Clinical trial · Observational
A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC
A Comparator Study of a Tasso Device to Traditional Venous Blood Sampling Methods for Complete Blood Count (CBC) With 5-part Differential in Patients With Leukemia, Lymphoma, and/or Other Blood Cell Disorders
NCT06360952CI-TRIAL-00077321unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders. This investigation will include a minimum of 40 sample sets from unique patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukocytosis | — | UNRESOLVED | — |
| Leukopenia | — | UNRESOLVED | — |
| Neutropenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tasso+ CBC | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- leukopenia
- description
- Participants that have abnormal laboratory results for leukopenia. Participants will be assigned to all cohorts they have abnormal laboratory results for.
- interventionNames
- Device: Tasso+ CBC
- label
- leukocytosis
- description
- Participants that have abnormal laboratory results for leukocytosis. Participants will be assigned to all cohorts they have abnormal laboratory results for.
- interventionNames
- Device: Tasso+ CBC
- label
- neutropenia
- description
- Participants that have abnormal laboratory results for neutropenia. Participants will be assigned to all cohorts they have abnormal laboratory results for.
- interventionNames
- Device: Tasso+ CBC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Willing and able to provide written (or electronic) informed consent prior to study entry 2. At least 18 years of age 3. Requiring a CBC blood test as part of the patient's standard of care 4. Have abnormal laboratory results of either leukopenia, leukocytosis or neutropenia. 5. Normal skin integrity and healthy skin appearance around the capillary collection site (upper arm/shoulder area on at least one side) Exclusion Criteria: 1. Unable to give full and free consent to participate in a study due to limited capacity or risk of undue influence or coercion (including but not limited to children, prisoners, individuals with diminished decision-making capacity, illiterate or educationally disadvantaged populations) or any other individual who is unable to give full and free consent in the judgement of the investigator 2. At the determination of the treating physician, unsuitable for enrollment due to severe immunocompromised status or other comorbidities.
References
Publications (0)
Data not yet available
No reference posted for this study.